| __timestamp | Taro Pharmaceutical Industries Ltd. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 179279000 | 18516000 |
| Thursday, January 1, 2015 | 186359000 | 34140000 |
| Friday, January 1, 2016 | 171785000 | 51872000 |
| Sunday, January 1, 2017 | 208136000 | 71772000 |
| Monday, January 1, 2018 | 198405000 | 97501000 |
| Tuesday, January 1, 2019 | 224169000 | 118590000 |
| Wednesday, January 1, 2020 | 245044000 | 169802000 |
| Friday, January 1, 2021 | 252314000 | 7491000 |
| Saturday, January 1, 2022 | 268225000 | 8799000 |
| Sunday, January 1, 2023 | 304629000 | 253598000 |
| Monday, January 1, 2024 | 324203000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals and biotechnology, understanding cost structures is crucial. Taro Pharmaceutical Industries Ltd. and Xencor, Inc. offer a fascinating comparison. Over the past decade, Taro's cost of revenue has shown a steady upward trend, peaking at approximately 324 million in 2024, a 81% increase from 2014. In contrast, Xencor's cost of revenue has been more volatile, with a significant spike in 2023, reaching around 254 million, a dramatic rise from just 7.5 million in 2021. This fluctuation highlights the dynamic nature of the biotech industry, where research and development costs can vary widely year to year. Notably, data for Xencor in 2024 is missing, leaving room for speculation on future trends. This comparison underscores the importance of strategic financial management in sustaining growth and competitiveness.
Cost of Revenue Comparison: AstraZeneca PLC vs Taro Pharmaceutical Industries Ltd.
Novartis AG vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Pfizer Inc. and Taro Pharmaceutical Industries Ltd.'s Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Xenon Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Xencor, Inc.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.